Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.51 |
| ▸ | XDH | P47989 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9170843 | 0.84 | XDH (0.52) | GDAXDH | |
| SCHEMBL16020627 | 0.78 | XDH (0.47) | GDAXDH | |
| SCHEMBL216788 | 0.76 | XDH (0.58) | GDAXDH | |
| SCHEMBL8397443 | 0.75 | XDH (0.44) | GDAXDH | |
| SCHEMBL766741 | 0.74 | GDA (0.63) | GDAXDH | |
| SCHEMBL29454397 | 0.73 | GDA (0.61) | GDAXDH | |
| SCHEMBL8717515 | 0.73 | XDH (0.61) | GDAXDH | |
| SCHEMBL6836089 | 0.73 | XDH (0.48) | GDAXDH | |
| Phosphoric Acid SCHEMBL27780171 | 0.72 | GDA (0.59) | GDAXDH | |
| Phosphoric Acid SCHEMBL27758690 | 0.72 | GDA (0.59) | GDAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | claimed |
| EP-1831235-B1 | LUNG-TARGETED DRUGS | UNIV CALIFORNIA (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2107909-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX Pharmaceuticals, Inc. (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082602-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LIVER DISORDERS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-1831235-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006066074-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | GDA 332/4885XDH 1262/4885 |
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | GDA 579/4885XDH 3650/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | GDA 579/4885XDH 3650/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | GDA 711/4885XDH 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.